Imaging and BioFluid Biomarkers in Amyotrophic Lateral Sclerosis
Status:
Completed
Trial end date:
2019-06-28
Target enrollment:
Participant gender:
Summary
This is a multicenter, 18-month study, which aims to identify imaging and biofluid biomarkers
in people with ALS to expand the understanding of ALS pathology, treatment targets, disease
progression, and anatomical differences between different disease phenotypes. This pilot
project is tailored to produce imaging tools that will allow researchers to conduct future
ALS clinical trials more efficiently which may in turn impact the pace for ALS drug
discovery.
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborators:
ALS Association Cedars-Sinai Medical Center The Methodist Hospital Research Institute The Methodist Hospital System